Researchers Studying Two Point-of-Care Tests to Gauge PGx Response to Anti-Platelet Drugs

Spartan Bioscience and Nanosphere are each working with academic research groups to determine the utility of their CYP2C19 tests for gauging response to Plavix at the point of care.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.